Novavax (NVAX) Tops Q2 EPS by 210c

Novavax (NASDAQ: NVAX) reported Q2 EPS of $0.58, $2.10 better than the analyst estimate of ($1.52). Revenue for the quarter came in at $424.43 million versus the consensus estimate of $237.39 million.

For earnings history and earnings-related data on Novavax (NVAX) click here.

You May Also Be Interested In

• Oracle reports earnings today: AI spending bet faces its toughest test yet
• Diamondrock Hospitality (DRH) PT Raised to $13.50 at Stifel
• Wynn Resorts plans $900M senior notes offering due 2035